Sterile and injectable formats: settle the regulatory category before you quote or make them
Record the intended route and the regulatory category for every injectable or sterile enquiry before anyone quotes or schedules it.
In Short
- Supplements are ingested forms.
- Sterile drugs: validated processes.
- Decide the category before quoting.
Brands and contract manufacturers asked to make IV, injectable or other sterile wellness products need to settle the regulatory category first. Opened: 21 U.S.C. 321(ff)(2) and 350(c)(1)(B) (GovInfo 2023 edition) and current eCFR 21 CFR 211.113 and 211.42(c)(10), up to date 1 October 2026. Not opened: FDA statements on injectable, ophthalmic or inhaled products sold as supplements, compounding rules under sections 503A and 503B, USP chapters 797 and 800, and EU GMP Annex 1. It is orientation, not legal advice. Sources checked 5 Oct 2026.
The Ingestion Test
Under 21 U.S.C. 321(ff)(2), a dietary supplement (A)(i) is intended for ingestion in a form described in 350(c)(1)(B)(i), or (ii) complies with 350(c)(1)(B)(ii); (B) is not represented as a conventional food or sole item of a meal or the diet; and (C) is labelled as a dietary supplement.
Intended route (invented enquiries)
- Capsule is listed in 350(c)(1)(B)(i).
- Check the rest of 321(ff).
More on the Ingestion Test
Section 350(c)(1)(B)(i) lists tablet, capsule, powder, softgel, gelcap or liquid form. Section 350(c)(1)(B)(ii) covers products not intended for ingestion in such a form that are not represented as conventional food or a sole item of a meal or the diet. Counsel decides how these words apply to an injection.
If the product is a drug
If counsel concludes the product is a drug, drug requirements apply, including current good manufacturing practice under 21 CFR Part 211 and an approval or other lawful pathway this guide does not cover. 211.113(b) requires appropriate written procedures designed to prevent microbiological contamination of drug products purporting to be sterile, and says they shall include validation of all aseptic and sterilization processes.
More on if the product is a drug
211.113(a) covers objectionable microorganisms in drug products not required to be sterile. These obligations sit with the manufacturer of record.
Facility Expectations for Aseptic Processing
21 CFR 211.42(c)(10) lists, as appropriate for aseptic processing: smooth, hard, easily cleanable floors, walls and ceilings; temperature and humidity controls; an air supply filtered through high-efficiency particulate air filters under positive pressure; a system for monitoring environmental conditions; a system for cleaning and disinfecting the room and equipment to produce aseptic conditions; and a system for maintaining equipment that controls aseptic conditions. A plant built for tablets and capsules is not designed around these elements, so treat a sterile enquiry as a capability question as well as a regulatory one.
Aseptic processing elements, 21 CFR 211.42(c)(10)
What this guide leaves out
Ophthalmic, nasal and inhaled products, pharmacy compounding, outsourcing facilities, USP chapters 797 and 800 and EU GMP Annex 1 are outside what was opened here. Their requirements are not described, and silence here is not a sign that they do not apply.
More on what this guide leaves out
If your enquiry involves any of them, open the current primary text or ask a specialist. Keep the record of which sources were consulted, when, and by whom, so a later reviewer can see what the decision rested on.
A decision record before you quote
Before quoting, record the intended route of administration, dosage form, sterility claim, intended label category and intended claims for each enquiry, then the regulatory decision and who made it. If the product is a drug, record the pathway counsel identified and whether your site holds the facilities, validation and procedures it needs.
Worked Example: Intake Record ENQ-0907
| Field | Entry | Owner |
|---|---|---|
| Route and form | Intravenous, sterile solution | Business development |
| Category decision | Drug, not a supplement | Regulatory counsel |
| Site capability | No aseptic suite; refer | Quality |
- Route and form
- Entry
- Intravenous, sterile solution
- Owner
- Business development
- Category decision
- Entry
- Drug, not a supplement
- Owner
- Regulatory counsel
- Site capability
- Entry
- No aseptic suite; refer
- Owner
- Quality
More on a decision record before you quote
Decline or refer work that sits outside your capability. People make each of these decisions; the record shows what they were based on and when they were made.
Questions
Can an IV vitamin product be sold as a dietary supplement?
Section 321(ff)(2)(A) requires intended ingestion in a listed form, or compliance with 350(c)(1)(B)(ii). An injection is not a listed form; counsel decides the category.
What does 21 CFR 211.113(b) require?
Written procedures designed to prevent microbiological contamination of drug products purporting to be sterile, including validation of all aseptic and sterilization processes.
Is a supplement plant ready for aseptic work?
Not by default. 21 CFR 211.42(c)(10) lists facility controls for aseptic processing, such as HEPA-filtered air under positive pressure and environmental monitoring.
Does V5 classify products or validate aseptic processes?
No. V5 keeps specifications, change records and batch records. Your regulatory team classifies products and your quality team owns validation.
Practical orientation, not legal advice. Rules differ by jurisdiction; your quality and compliance team decides what applies.
Keep reading
21 CFR 111 Readiness: Identity, Master and Batch Records
Africa Supplement Regulation: SAHPRA, NAFDAC & Kenya PPB
Supplement Allergen Control: Validated Cleaning and Labelling
ASEAN Supplement Rules: BPOM, Thai FDA, Vietnam and PH FDA
CBD in Dietary Supplements: The Federal Drug Exclusion and Hemp Definition
Children's Supplements: Iron Packaging, Warnings and Age-Group Labels